GC Aesthetics is excited to share the beginning of a new, exciting, and promising chapter for our company, as our breast implants are now directly represented in Colombia.
Last quarter, we established GCA Colombia, our newest subsidiary aligned with our GC Aesthetics strategy to serve our brand users directly where and when it makes sense.
GCA is now directly present in the fourth largest Latin American market, and one of the top 10 in the world. We bring the GCA ethos, legacy and great products and brands to serve the plastic surgery community.
Even with a challenging environment for elective procedures due to COVID-19 related lockdowns, we shipped our first orders (of both Eurosilicone and Nagor products) to Medellín, Bucaramanga, Bogotá and Pereira and the first surgeries have been able to take place safely.
Our Colombian team is enthusiastic about our on-going activities and continues to virtually call on customers or visit them where regulations allow for in-person calls.
“Our brands have long been used in Colombia; with our direct presence, we will drive them to new levels with dedicated work and enthusiasm.”
Our office is located in Bogotá and we invite surgeons to get in contact with us to learn more about our pre-surgery, surgery and post-surgery offerings and find out how our solutions at GC Aesthetics can support you.
GC Aesthetics Colombia, S.A.S.
Calle 125 Bis 20-75 Of. 203
Barrio Santa Bárbara
Bogotá, D.C. 110111 Colombia
About GC Aesthetics
GC Aesthetics is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal journey. Throughout 40 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality silicone breast implants under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. We have sold more than 3 million implants across 70 countries and our products are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.